What is Fragment-based Drug Discovery?
Fragment-based drug discovery (FBDD) additionally acknowledged as fragment-based lead discovery (FBLD) is a technique used for discovering lead compounds as section of the drug discovery process. Fragments are small natural molecules which are small in dimension and low in molecular weight. It is based totally on figuring out small chemical fragments, which may also bind solely weakly to the organic target, and then developing them or combining them to produce a lead with a greater affinity. Fragment-based drug discovery (FBDD) is a effective approach to enhance powerful small-molecule compounds beginning from fragments binding weakly to targets. As FBDD famous a number of blessings over high-throughput screening campaigns, it will become an appealing method in target-based drug discovery.
|Unit||Value (USD Million)|
|Key Companies Profiled||Astex Pharmaceuticals (United Kingdom), Alveus Pharmaceuticals (India), Beactica (Sweden), Charles River Laboratories (United States), Crown Bioscience (United States), Emerald BioStructures (United States), Evotec (Germany), Kinetic Discovery (United Kingdom), Proteros Fragments (Germany) and Structure Based Design (United States)|
The market study is broken down by Type (Fragment Screening and Fragment Optimization) and major geographies with country level break-up.
The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Fragment-based Drug Discovery market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Astex Pharmaceuticals (United Kingdom), Alveus Pharmaceuticals (India), Beactica (Sweden), Charles River Laboratories (United States), Crown Bioscience (United States), Emerald BioStructures (United States), Evotec (Germany), Kinetic Discovery (United Kingdom), Proteros Fragments (Germany) and Structure Based Design (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sygnature Discovery (United Kingdom) and Sprint Bioscience (Sweden).
AdvanceMarketAnalytics has segmented the market of Global Fragment-based Drug Discovery market by Type, Application and Region.
On the basis of geography, the market of Fragment-based Drug Discovery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-users, the sub-segment i.e. Academic and Research Institutions will boost the Fragment-based Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. NMR Spectroscopy will boost the Fragment-based Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
In 2021, Astex Pharmaceuticals, Inc., a utterly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., primarily based in Tokyo, Japan, introduced up to date medical data, which includes median normal survival (mOS), from the ASCERTAIN section three trial of INQOVI®, the company’s orally administered fixed-dose aggregate of decitabine and cedazuridine (ASTX727 or DEC-C) in adults with intermediate and high-risk myelodysplastic syndromes (MDS) together with continual myelomonocytic leukemia (CMML).
- High-Tech Will Fuel Advancement in R&D
- Data Analytics Will Accelerate Biotechnology Innovation
- Emerging Markets Will Drive Innovation
- Increased Conflict between Affordability and Access
- Increasingly used in the Pharmaceutical Industry, For Reducing Attrition and Providing Leads for Previously Intractable Biological Targets
- Availability of Wide Range of Assay Options for High Hit Rates of Fragment-Based Screens
- It is a complex Method
- Expensive Method
- Reduced Demand for Prescription Medicine
- Growing Competition from Generic Pharmaceuticals
- Pharmaceutical Fraud
- Rising Consumer Expectations and Difficulties Managing Brand Health
- Data Breaches and Other Cybersecurity Threats
- Supply Chain Disruptions
Key Target AudienceFragmented-based Drug Discovery Manufacturers, Raw Materials Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
About ApproachTo evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Frequently Asked Questions (FAQ):
1. What all players are profiled in the study?
The standard version of the report profiles players such as Astex Pharmaceuticals (United Kingdom), Alveus Pharmaceuticals (India), Beactica (Sweden), Charles River Laboratories (United States), Crown Bioscience (United States), Emerald BioStructures (United States), Evotec (Germany), Kinetic Discovery (United Kingdom), Proteros Fragments (Germany) and Structure Based Design (United States) etc.
2. Can we have customized study for Fragment-based Drug Discovery Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
3. What would be the Market Size of Fragment-based Drug Discovery Market by 2027?
Analysts at AMA estimates Fragment-based Drug Discovery Market to reach USD Million by 2027.